JPRN-UMIN000046044已完成未知
Efficacy and Safety of the BNT162b2, mRNA-1273, and ChAdOx1-S COVID-19 Vaccine in Patients who have received allogeneic hematopoietic stem cell transplantation for hematological diseases: An observational study. - Allogeneic HSCT COVID19 vaccine study
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 16years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Those who are judged by the principal investigator or sub-investigator to be inappropriate for participation in the study. 2) Patients with a history of COVID-19 3) Patients who are unable to communicate with others
研究者
相似试验
已完成
不适用
Efficacy and Safety of the BNT162b2, mRNA-1273, and ChAdOx1-S COVID-19 Vaccine in Patients with hematological diseases treated with rituximab or obinutuzumab: An observational study.B cell non-Hodgkin lymphoma, Post-transplant Lymphoproliferative Disorders, Idiopathic thrombocytopenic purpura, thrombotic thrombocytopenic purpuraJPRN-UMIN000046043Kobe City Medical Center General Hospital152
已完成
不适用
Immunogenicity and safety of BNT162b2 mRNA vaccine in outpatients on dialysis: Double center prospective observational study in Japadialysis patientsJPRN-UMIN000044500Shonan Fujisiawa Tokushukai Hospital150
已完成
2 期
Phase IIb study on the safety and efficacy of BM32, a recombinant hypoallergenic vaccine for immunotherapy of grass pollen allergygrass pollen allergy10001708NL-OMON39223Biomay AG20
进行中（未招募）
不适用
A trial comparing efficacy and safety of NN1250 and insulin glargine in subjects with type 2 diabetestype 2 diabetes mellitusMedDRA version: 12.0Level: LLTClassification code 10045242Term: Type II diabetes mellitusEUCTR2009-010662-28-IEovo Nordisk A/S450
进行中（未招募）
不适用
A trial comparing efficacy and safety of NN1250 and insulin glargine in subjects with type 2 diabetesEUCTR2009-010662-28-GBovo Nordisk A/S450